893755-98-1

Basic information

• Product Name: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-OL
• Synonyms: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-OL;1-(2-Pyrimidinyl)-4-piperidinol;N-(2-Pyrimidinyl)-4-hydroxypiperidine
• CAS NO: 893755-98-1
• Molecular Formula: C₉H₁₃N₃O
• Molecular Weight: 179.22
• Mol File: 893755-98-1.mol

Chemical Properties

• Boiling Point: 365.5°C at 760 mmHg
• Flash Point: 174.8°C
• Appearance: /
• Density: 1.234g/cm³
• Vapor Pressure: 5.53E-06mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-OL(893755-98-1)
• EPA Substance Registry System: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-OL(893755-98-1)

Safety Data

• Hazardous Substances Data: 893755-98-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrimidin-2-yl-piperidin-4-ol is used as a chemical compound for its potential biological activities, which may contribute to drug development. Its unique structure allows it to be a subject of interest for medicinal chemistry research, where it could be utilized in the creation of new therapeutic agents.
Given the provided materials, specific applications and reasons for the use of 1-Pyrimidin-2-yl-piperidin-4-ol are not detailed. However, its potential use in the pharmaceutical industry is based on its status as a heterocyclic organic compound with properties that could be harnessed for medicinal purposes. Further research would be necessary to explore and confirm its specific applications and benefits in various therapeutic areas.

InChI:InChI=1/C9H13N3O/c13-8-2-6-12(7-3-8)9-10-4-1-5-11-9/h1,4-5,8,13H,2-3,6-7H2

Upstream product

• 116247-92-8 1-(2-Pyrimidinyl)-4-piperidinone 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1722-12-9 2-chloropyrimidine 

Downstream Products

• 1190364-42-1 1-(4-(methylsulfonyl)phenyl)ethanone O-5-methyl-6-(1-(pyrimidin-2-yl)piperidin-4-yloxy)pyrimidin-4-yl oxime 
• 1001399-08-1 7-[2-fluoro-4-(methylsulfonyl)phenyl]-4-{[1-(1,4,5,6-tetrahydro-2-pyrimidinyl)-4-piperidinyl]oxy}-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1258603-03-0 trans-5-(4-((5-methyl-6-((1-(pyrimidin-2-yl)piperidin-4-yl)oxy)pyrimidin-4-yl)oxy)phenyl)-1,3,2-dioxathiane 2-oxide 
• 1258603-02-9 cis-5-(4-((5-methyl-6-((1-(pyrimidin-2-yl)piperidin-4-yl)oxy)pyrimidin-4-yl)oxy)phenyl)-1,3,2-dioxathiane 2-oxide 
• 1258604-40-8 2-(4-(5-methyl-6-(1-(pyrimidin-2-yl)piperidin-4-yloxy)pyrimidin-4-yloxy)phenyl)propane-1,3-diol 
• 1258604-39-5 4-(4-(2,2-dimethyl-1,3-dioxan-5-yl)phenoxy)-5-methyl-6-(1-(pyrimidin-2-yl)piperidin-4-yloxy)pyrimidine 
• 1325211-63-9 (2R,3R)-2-(2,4-difluorophenyl)-3-((1-(pyrimidin-2-yl)piperidin-4-yl)oxy)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 

Relevant articles and documents

Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists

GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA

This invention relates to methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia.

GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

Multicyclic compounds and methods of their use

This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.